He's Been the Regulator, the Sponsor, and the Consultant.

Dr. Timothy R. Cote,
</br>MD, MPH

Dr. Timothy R. Cote,

MD, MPH

As the former Director of the FDA’s Office of Orphan Products Development, Dr. Cote was the ultimate decision maker on orphan drug designation applications and made that call more than 1,400 times. In the 15 years since, he has built regulatory consultancies, run his own clinical stage orphan biotechs, and written over 900 designation applications.

Only Orphans Cote exists to put that experience behind every submission his team builds. First time applicants succeed about 35 percent of the time. Applications from this office succeed about 95 percent. That is not luck.

Sept 2007 – June 2011
1,400+

Orphan drug designation applications personally decided as Director of the FDA's Office of Orphan Products Development, resulting in 200 orphan drugs reaching market.

May 2012 – June 2017
500+

Clients served through Cote Orphan Consulting, Dr. Cote's first boutique consultancy, acquired by IQVIA.

June 2021 – Present
200+

Clients served by Only Orphans Cote, applying the same standard from a dedicated boutique team.

January 2025 – Present
90,000+

Founded by Dr. Cote to develop a topical therapy for high grade dysplasia, an official population of 90,000+ US patients. The program is now headed to the clinic.

The Team Behind Every Engagement

With a focus on successful outcomes, your program will be managed by a highly professional team of specialists guided by Dr. Cote's unique regulatory experience.

Timothy Cote, MD, MPH

Founder & CEO

Timothy Cote, MD, MPH

Founder & CEO

Dr. Timothy R. Coté, MD MPH, is a renowned national regulatory expert in orphan drug regulatory affairs. He is founder and CEO at Only Orphans Cote with offices in Cambridge MA and Washington DC, leading a select team of experts in rare diseases and orphan drug regulatory affairs strategy. As former Director of the Office of Orphan Product Development (OOPD) at FDA, between 2007 – 2011, Dr. Cote led the agency’s efforts in implementing the Orphan Drug Act and personally signed decisions on 1400+ orphan drug designation applications. Dr. Coté received a bachelor’s degree from Syracuse University, his medical doctorate from the Howard University College of Medicine and a Master of Public Health (MPH) from the Harvard School of Public Health.

Preeti Putcha, PhD

Regulatory Affairs Lead

Preeti Putcha, PhD

Regulatory Affairs Lead

Preeti brings over 12 years of experience in Translational Medicine across preclinical and clinical sectors. She is excited about the rapid and novel advances defining therapeutics. She received a doctorate in cell biology and pathology from Columbia University and went on to consulting, providing subject matter expertise towards tailored therapeutics across cardiometabolic, neurodegenerative, and oncological fields. She has worked with a diverse array of clients and now applies her background to rare disease profiles.

Ishani Thakkar, PhD, MS

Regulatory Affairs Lead

Ishani Thakkar, PhD, MS

Regulatory Affairs Lead

Ishani has a PhD in neuroscience and an MS in biomedical engineering. She has extensive experience in medical writing and scientific communication, which she now brings to the regulatory affairs team at Only Orphans Cote.

Tina Wang, MA

Business Development Lead

Tina Wang, MA

Business Development Lead

As Business Development Lead at Only Orphans Cote, Tina leverages her expertise in sales, digital marketing, and multilingual communication to drive business growth across the U.S. and Asia. She manages client relationships, develops tailored proposals for regulatory consulting services, and leads strategic outreach initiatives.

Eric Smith-Sokol

Business Development Lead

Eric Smith-Sokol

Business Development Lead

Eric graduated from the University of Colorado class of 2020 with a bachelor’s degree in communication. His background is primarily focused on business development with experience in the consulting industry.

Dina Elnaggar, MD, MA, MSc

Chief of Staff

Dina Elnaggar, MD, MA, MSc

Chief of Staff

Dina Elnaggar MD, MA, MSc brings more than 25 years of experience in the fields of human development and strategic communications in multinational organizations. Prior to joining OOC as Chief of Staff, she worked full time as a Communications and Stakeholder Engagement Team Lead at the World Bank. In her current role as Chief of Staff, she is responsible for managing work culture while supporting corporate processes and team management.

A Practice Built for Global Programs

Headquartered in Cambridge, Massachusetts, with wholly owned subsidiaries in Ireland and the UK, Only Orphans Cote guides biotech and pharma clients across the world through FDA and EMA orphan drug designation pathways, including gene and cell therapy programs.

Global Programs Map

Conferences & Events 2027

Biotech Showcase 2027

January 11-13, San Francisco, CA

BIO Partnering at JPM Week 2027

January 11-15, San Francisco, CA

Rare Disease Summit (Access USA) 2027

March 23-25, National Harbor, MD

BIO-Europe Spring 2027

April 5-7, Lyon, France

BIO International Convention 2027

June 7-10, Philadelphia, PA

BIO-Europe 2027

Late October, Stockholm, Sweden

Frequently Asked Questions

Dr. Cote is the primary point of contact for every client. He is well supported by a team of business development associates and regulatory affairs associates who manage the administration of meetings and contracts, and the drafting of manuscripts, respectively. However, all critical work is overseen directly by Dr. Cote. Every word submitted is his responsibility, every meeting is with him, and your success is placed in his hands. Clients can count on his personal attention and accountability throughout the process.

In the conduct of two consultancies over 8 years, Dr. Cote has personally written over 900 orphan designation applications, certainly more than anyone else on the planet.

No. Programs come to us from biotechs and pharma companies well beyond the U.S. The same FDA and EMA expertise applies wherever your program is based.

Yes. Between 2012 and 2017, Dr. Cote personally submitted more European orphan drug designation applications than any single European entity. This is in addition to years of direct collaboration with the EMA's Committee on Orphan Medicinal Products while he was still at the FDA. That depth carries into every EMA program Only Orphans Cote takes on today.

Every orphan drug is unique and special.
Share your story with us. We'll set you on the right path.

Book a Free Consultation